Active, not recruitingPhase 3NCT03553836
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Pembrolizumab(biological)
- Enrollment
- 976 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2018 – 2033
Study locations (30)
- University of Arizona Cancer Center ( Site 0121), Tucson, Arizona, United States
- UCSD Moores Cancer Center ( Site 0133), La Jolla, California, United States
- The Angeles Clinic and Research Institute ( Site 0029), Los Angeles, California, United States
- UCLA Hematology & Oncology ( Site 0130), Los Angeles, California, United States
- John Wayne Cancer Institute ( Site 0026), Santa Monica, California, United States
- University of Colorado Cancer Center ( Site 0027), Aurora, Colorado, United States
- Yale University ( Site 0035), New Haven, Connecticut, United States
- Mayo Clinic Florida ( Site 0024), Jacksonville, Florida, United States
- Moffitt McKinley Outpatient Center ( Site 0131), Tampa, Florida, United States
- Winship Cancer Institute of Emory University ( Site 0046), Atlanta, Georgia, United States
- Northside Hospital ( Site 0115), Atlanta, Georgia, United States
- Northwestern Medical Group ( Site 0135), Chicago, Illinois, United States
- The University of Chicago Medical Center ( Site 0007), Chicago, Illinois, United States
- Advocate Medical Group-Park Ridge ( Site 0025), Park Ridge, Illinois, United States
- University of Iowa Hospital and Clinics ( Site 0001), Iowa City, Iowa, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03553836 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC
See all trials for Autosomal dominant multiple pterygium syndrome →